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1320Available online 31 July 2020We established an international consortium to review and discuss relevant clinical evidence in order to develop expert
consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-
related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant
clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one
patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and
voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached.
Overall, the expert panel agreed on 28 consensus statements that can be used to overcome many of the clinical
and technical areas of uncertainty ranging from diagnosis to therapeutic planning and treatment during the COVID-
19 pandemic.INTRODUCTION
The disease course of individuals contracting severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
is phenotypically diverse. Many patients suffer only mild
symptoms and it is becoming increasingly apparent from
antibody (Ab) data that others suffer no symptoms at all but
can actively carry and transmit the infection. However, at
the other end of the spectrum, some individuals develop
very severe symptoms and can follow an extreme pheno-
type with the development of respiratory failure, cytokine
release syndrome and multi-organ failure.1 Subgroups of
SARS-CoV-2-related disease (COVID-19) patients have been
identified who appear to be at increased risk of extremeondence to: Prof. Giuseppe Curigliano, ESMO Guidelines Committee,
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https://doi.org/10.1016/j.annonc.2020.07.010morbidity and mortality, including those of advancing age,
male sex and those with comorbidities such as hyperten-
sion, chronic lung disease, diabetes and cancer.1 Since the
start of the global spread of COVID-19 in early 2020, pa-
tients with cancer were designated as a particularly
vulnerable subgroup of the population. Cancer patients
have been reported to be both at increased risk of con-
tracting SARS-CoV-2 infection and of running a more severe
disease course, with a higher proportion requiring greater
levels of intensive care, having a more rapidly evolving
disease and an increased risk of death.2e4 However, the
term ‘cancer’ encompasses a myriad of diseases with a
diverse array of primary tumour subtypes and stages
affecting a heterogeneous group of patients of all ages, all
of which result in very different cancer prognoses and
outcomes. Therefore, labeling all cancer patients as ‘COVID-
19 vulnerable’ is probably neither reasonable nor informa-
tive. As a consequence of generic advice given to ‘COVID-19
vulnerable’ members of the population, cancer patients (ofVolume 31 - Issue 10 - 2020
G. Curigliano et al. Annals of Oncologyany age, sex or tumour subtype and stage) have been
labeled as high risk for COVID-19 and this has led to
sweeping changes in cancer management for all cancer
types over the last few months, including abbreviation
of radiotherapy (RT), switching from intravenous (i.v.) to oral
chemotherapy (ChT) regimens and the avoidance of
immunotherapy.5e7 These changes, perhaps reasonable in
an acute pandemic situation, were instigated with very little
evidence to support them. Based on the lack of evolving
evidence, there has been little attempt to define the indi-
vidualised risk for a given patient, taking into consideration
their primary tumour type, stage, age and sex. A large,
international and mutidisciplinary consortium was estab-
lished to review and discuss clinical evidence in order to
develop expert consensus statements on key areas of con-
troversy and technical questions. These consensus state-
ments provide clear recommendations for the management
of cancer patients across the multidisciplinary team (MDT)
in order to support physicians in optimising the cancer care
pathway and improving clinical outcomes. The main goal is
to help MDTs to deliver the best possible care during the
COVID-19 pandemic.
METHODS
A steering committee (SC) prepared a series of questions to
be voted upon at the consensus meeting. The multidisci-
plinary expert panel was compiled based on nominations
from the European Society for Medical Oncology (ESMO)
Guidelines Committee Chair G. Pentheroudakis and
Co-Chair G. Curigliano. The SC consisted of 15 members
(manuscript authors) with expertise across a wide range of
malignant diseases. In order to develop the clinical ques-
tions to be addressed at the consensus meeting, the SC
reviewed relevant clinical evidence and basic research in
cancer patient management. Insights from the literature
review were supplemented with expert clinical opinion to
develop 10 working packages (WPs) (outlined in Table 1)
with draft consensus statements included in the toolbox.
The final Member Panel (including the SC members) con-
sisted of 62 experts (including two individualsdJ.Y. Douil-
lard and D. Trapanidwho did not participate in the voting
of consensus recommendations) and 1 patient advocate. A
modified Delphi process was conducted, including prepa-
ration, consensus and reporting. A feedback procedure by
the SC panel was implemented via e-mail. Background in-
formation including the WPs were sent to panellists twice
between 29 May 2020 and 3 June 2020. The SC incorpo-
rated all comments and suggestions and any disagreements
were discussed and resolved. WPs were then sent for a
second anonymous review to all panellists.
RESULTS: CLINICAL QUESTIONS AND STATEMENTS
Which groups of patients should be offered face-to-face
consultations if feasible during the COVID-19 pandemic?
STATEMENT 1: Telehealth and digital health in oncology
can be an excellent tool for real-time video consultations
for primary care triage and interventions such asVolume 31 - Issue 10 - 2020counselling, medication prescribing and management,
management of long-term treatment and post-discharge
coordination supported by remote-monitoring capabil-
ities. It can also be an excellent tool for wellness in-
terventions and in areas such as health education, physical
activity, diet monitoring, health risk assessment, medica-
tion adherence and cognitive fitness.
Face-to-face consultations covering the delivery of key
cancer-related information (e.g. new cancer diagnosis/
treatment plan, disease relapse/progression and no further
cancer treatment decisions) may be more effective and
empathetic than remote consultations (video or telephone).
In addition, patients with complex cancer needs should be
considered for face-to-face consultation. The risks of travel
for the patient and SARS-CoV-2 exposure need to be
considered. If practical, measures in the clinic should be
implemented for patients to be allowed one person with
them for support during the face-to-face consultation.8Is there a possibility to tailor the intensity of care and
social measures for cancer patients according to local
COVID-19 incidence rates?
STATEMENT 2: Cancer care prioritisation and cancer care
intensity should be adapted to the pandemic scenario
[from 1 to 4 according to the European Centre for Disease
Prevention and Control (ECDC)], to local R0 index and to
health facilities and resources.
R0 is the measure used to track how many people on
average will be infected for every person who has the dis-
ease and is the most internationally used index. R0 may also
be used locally to shape prioritisation of treatments and
safety measures at a local level. Possible R0 cut-off levels
are <0.5, 0.5e1, >1e2, >2e3 and >3.9,10
Important factors are the status of the viral outbreak in
terms of availability of hospital technical and human
resources as well as on-site intensive care unit (ICU)
ventilation capacity.11 Expert and specialised multidisci-
plinary discussion should be available to define the priority
level of the cancer treatment.
In a situation where resources are not exhausted, the
general rule is that operations planned for cancer patients
that cannot be postponed for 3 months should be sched-
uled as soon as possible, taking the necessary precautions
(including viral screening) so not to compromise the onco-
logical prognosis of the patient. In situations where re-
sources are exhausted, only emergency services can be
provided and alternative cancer therapeutic modalities that
are still available must be administered with a plan put in
place in accordance with health authorities.
For thoracic surgery, surgical procedures should be done
as soon as possible for solid or predominantly solid lung
nodules or presumed lung cancer >2 cm or with positive
nodes, symptomatic mediastinal tumours or oesophageal
cancer T1b; surgery may be deferred in cases of pre-
dominantly ground glass nodules, tumours <2 cm or
tumours of indolent histologydcarcinoid or thymomadbut
also for high-risk patients likely to require prolonged ICUhttps://doi.org/10.1016/j.annonc.2020.07.010 1321





STATEMENT 1: Telehealth and digital health in oncology can be an excellent tool for real-time video consultations for
primary care triage and interventions such as counselling, medication prescribing and management, management of long-
term treatment and post-discharge coordination supported by remote-monitoring capabilities. It can also be an excellent
tool for wellness interventions and in areas such as health education, physical activity, diet monitoring, health risk






STATEMENT 2: Cancer care prioritisation and cancer care intensity should be adapted to the pandemic scenario (from 1 to 4
according to the ECDC), to local R0 index and to health facilities and resources.
STATEMENT 3: When feasible in the context of available resources, cancer patients requiring admission to hospital for
cancer treatment should be tested for SARS-CoV-2 regardless of symptoms or chest radiological findings if considered at
high risk of mortality in case of SARS-CoV-2 infection.
STATEMENT 4: Perform a point-of-care risk assessment to assess the likelihood of SARS-CoV-2 infection, including the
clinical presentation of the patient and a review of clinical, epidemiological and travel history. This should aim to achieve a
rapid evaluation of the risk of infectiousness based on signs, symptoms and the procedures likely to result in infectious
respiratory droplets and aerosols.
STATEMENT 5: PPE should be provided to all health care professionals and used meticulously. Health care workers in
enclosed spaces should wear eye protection, a gown and a surgical mask or, if available, an FFP, and practice hand hygiene









STATEMENT 6: To lower the risk of febrile neutropaenia, consider expanding the indication of G-CSF for patients with
intermediate (10%e20%) and high risk of febrile neutropaenia (>20%) and specifically for elderly patients with
comorbidities.
STATEMENT 7: In patients with cancer and COVID-19, there is an increased risk of thromboembolic events and associated





STATEMENT 8: Detection of SARS-CoV-2 RNA by means of RT-PCR is the current gold standard for diagnosis of acute
infection with the causative organism of COVID-19.
STATEMENT 9: Serological Ab tests cannot replace testing for the SARS-CoV-2 nucleic acid. They can be used for longitudinal
detection of seroconversion and seroprevalence in individuals previously positive for SARS-CoV-2.
STATEMENT 10: Patients’ infectivity for SARS-CoV-2 is determined by the presence of the virus in different body fluids,
secretions and excreta. The persistence and clearance of viral RNA from different specimens of patients with COVID-19
remain unclear. We need longitudinal studies to distinguish early asymptomatic patients testing positive from patients
recovered from COVID-19 who still test positive by RT-PCR as their infectivity may differ.
Use of immunotherapy STATEMENT 11: For the approved indication of (neo)adjuvant treatment, where there is a significant survival benefit, ICIs
should not be withheld or delayed in the absence of SARS-CoV-2 infection. In patients who have tested positive for SARS-
CoV-2, the (neo)adjuvant ICI should be postponed until recovery.
STATEMENT 12: For patients with metastatic melanoma, intermediate/poor-risk mRCC, PD-L1-positive NSCLC and
hepatocellular carcinoma, where there is a clear survival benefit, ICI treatment should be interrupted because of COVID-19.
Restarting ICI treatment should be considered after complete resolution of COVID-19 following negative RT-PCR testing. A
combination of ICI with cytotoxic ChT can be considered and discussed with patients when the costebenefit ratio is
favourable (OS gain) according to patient risk factors and preference.
STATEMENT 13: High-dose steroids may represent a potential risk factor for mortality in cancer patients who are infected
with SARS-CoV-2. In case of the need to manage a G3e4 irAE, if possible, switch to another immunosuppressant agent.
STATEMENT 14: The combination of anti-CTLA4 plus anti-PD-(L)1 should be given if the patient’s disease requires such ICI
treatment (in case of an approved indication), in view of the lack of evidence that sequencing anti-PD-(L)1 and anti-CTLA4
agents is as effective or less toxic.
STATEMENT 15: For the differential diagnosis of an irAE from SARS pneumonitis, a nasopharyngeal swab should be obtained
for PCR and a high-resolution thoracic CT scan should be carried out. If negative, a BAL should be considered (increased risk
for pulmonary oncology team) for differential diagnosis of irAEs versus COVID-19.
Use of targeted TKI
therapies
STATEMENT 16: TKIs of the PI3K/AKT/mTOR or RAS/RAF/MEK axis can interfere with critical pathways involved in innate or
adaptive immune responses. The decision to withhold therapy with these TKIs depends on the riskebenefit balance.
Consequently, the magnitude of benefit (ESMO-MCBS) from the TKI should be considered in a tumour-specific context in the
decision-making process until more clinical data are available.
STATEMENT 17: Due to the acute kinetics of COVID-19, it is reasonable to withhold TKI therapy in patients with
oncologically stable disease until the patient recovers. TKIs may not be interrupted in patients with less severe COVID-19 or




STATEMENT 18: For breast cancer patients in the curative setting, regimens and doses of adjuvant/neoadjuvant systemic
therapies should be followed, always preceded by a multidisciplinary discussion, riskebenefit analysis and discussion with
the patient. Significant delays should be avoided and protective/supportive measures implemented (growth factor support,
less immunosuppressive regimen selection).
STATEMENT 19: In stage IIeIII NSCLC, adjuvant ChT (with concurrent or sequential RT in stage III) is recommended for fit,
young patients without significant comorbidities, after an informed discussion with the patient. In the event of lack of
surgical resources, neoadjuvant ChT followed by surgery may be considered in highly selected subsets of patients.
STATEMENT 20: Switching to SCPRT (5 3 5 Gy) in rectal cancer rather than standard long-course CRT schedules should be
considered.
RT strategies during the
COVID-19 pandemic
STATEMENT 21: Patients undergoing adjuvant or definitive lung RT are at risk of severe complications from COVID-19. In
order to reduce the risks of treatment and hospital attendances during the COVID-19 pandemic, the use of reduced-
fractionation RT should be discussed by the multidisciplinary tumour board as well as with the patient in order to balance
the risk-benefit of the approach.
STATEMENT 22: In the case of a diagnosed COVID-19 patient with lung cancer, we recommend continuing curative-intent
thoracic RT, taking into consideration the severity of the COVID-19 clinical syndrome, the risk of tumour recurrence/
progression with treatment interruption and the local resources.
Continued
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STATEMENT 23: Active and progressing status of cancer, advanced age, poor PS, smoking status, comorbidities and possibly
type of cancer (haematological, thoracic malignancies) and administration of cytotoxic ChT have been initially identified as
significant risk factors for severity and mortality of COVID-19.
STATEMENT 24: A decision on ICU transfer depends on the ICU resource strain and is to be adapted according to the R0
index and ECDC pandemic scenario; the ethical value of maximising the number of patients who survive COVID-19 with a
reasonable life expectancy has the highest priority.
Clinical trial activities in
the COVID-19 era
STATEMENT 25: The riskebenefit profile for including an individual patient in a clinical trial should be adapted to the R0
index and case load of the pandemic as well as health care organisation characteristics and resources.
STATEMENT 26: During the COVID-19 pandemic, deviations from a clinical trial protocol (for riskebenefit reasons) may be
considered provided there is rigorous documentation in the medical record of the patient and that this is communicated as
soon as possible to the sponsor. There are no acceptable deviations in safety reporting.
STATEMENT 27: During the COVID-19 pandemic, we should continue lobbying for promoting clinical cancer research to find
better therapeutic options for patients with neoplasms. Cancer is and will continue to be one of the most significant causes
of morbidity and mortality.
STATEMENT 28: While we globally continue promoting clinical cancer research as the only way to find better therapeutic
options and to improve cancer prognosis, we should continue ranking priorities in terms of value for the most appropriate
clinical research.
Ab, antibody; BAL, broncho-alveolar lavage; ChT, chemotherapy; COVID-19, severe acute respiratory syndrome coronavirus 2-related disease; CRT, chemoradiotherapy; CT,
computed tomography; CTLA4, cytotoxic T-lymphocyte-associated protein 4; ECDC, European Centre for Disease Prevention and Control; ESMO-MCBS, ESMO-Magnitude of
Clinical Benefit Scale; FFP, filtering face piece; G, grade; G-CSF, granulocyte colony-stimulating factor; ICI, immune checkpoint inhibitor; ICU, intensive care unit; irAE, immune-
related adverse event; LMWH, low molecular weight heparin; mRCC, metastatic renal cell carcinoma; mTOR, mammalian target of rapamycin; NOAC, novel oral anticoagulant;
NSCLC, non-small-cell lung cancer; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3K, phosphoinositide 3-kinase; PPE, personal
protective equipment; PS, performance status; RT, radiotherapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCPRT, short-course preoperative radiotherapy;
TKI, tyrosine kinase inhibitor; WP, working package.
G. Curigliano et al. Annals of Oncologyadmissions. Alternative non-surgical approaches may be
considered for early-stage tumours including stereotactic
ablative RT or other interventional procedures.Do all cancer patients have to be tested for COVID-19
infection before hospital admittance?
STATEMENT 3: When feasible in the context of available
resources, cancer patients requiring admission to hospital
for cancer treatment should be tested for SARS-CoV-2
regardless of symptoms or chest radiological findings if
considered at high risk of mortality in case of SARS-CoV-2
infection.
It is imperative that cancer patients requiring inpatient
admission with fever and upper respiratory symptoms or
chest radiographical findings with suspected COVID-19 (new
peripheral opacities) should be segregated/isolated and
have a COVID-19 swab carried out (unless done within the
past 48 h). Once a negative COVID-19 swab is obtained,
they can be transferred to a regular ward.
COVID-19 management wards need to be segregated,
with airflow and health staff flow management. Patients
that are confirmed as COVID-19 positive should be admitted
to these wards. Patients under investigation for COVID-19
should also be segregated until a negative swab is
obtained. Health care workers should wear full personal
protective equipment (PPE) and be segregated until the
patient has a negative swab.12e14
When necessary resources are available and in the
context of a high local SARS-CoV-2 spread and case load, all
cancer patients requiring hospital admission should be
screened with a RT-PCR pharyngeal swab within 48 h. In all
cases, even when universal PCR screening is not feasible, it
is recommended to test cancer patients requiring admission
for fever and symptoms at admission and to have as muchVolume 31 - Issue 10 - 2020separation as possible from other patients and use of PPE
for health care workers. A patient who is transferred across
hospital wards/departments for examinations must wear
proper PPE. Further investigations should be prioritised to
those that are urgent or needed for life-threatening treat-
ments until a negative COVID-19 swab is obtained.Which preventive measures do you suggest for patients
coming to outpatient cancer clinics?
STATEMENT 4: Perform a point-of-care risk assessment to
assess the likelihood of SARS-CoV-2 infection, including the
clinical presentation of the patient and a review of clinical,
epidemiological and travel history. This should aim to
achieve a rapid evaluation of the risk of infectiousness
based on signs, symptoms and the procedures likely to
result in infectious respiratory droplets and aerosols.
All cancer patients for outpatient treatment should be
screened before entry for fever (temperature >37.5C) and
upper respiratory symptoms. If positive on symptom screen,
the patient should not be allowed to enter the cancer
centre and advised that a swab should be taken to test for
COVID-19. Once a swab is confirmed as negative, the pa-
tient can proceed to enter the cancer centre.15 Once point-
of-care testing is readily available, all cancer patients
entering an outpatient setting should be advised to have a
negative test before entry. In the presence of available re-
sources, we suggest carrying out a swab within 48 h before
each treatment cycle, testing for fever and symptoms at the
cancer centre entrance and to have as much separation as
possible from other patients and health care workers with
the use of PPE. Testing policies may vary according to local
resources and policies. During treatment, the patient must
wear PPE. In case of shortages of testing equipment, we
suggest testing at least all patients undergoing ChT.https://doi.org/10.1016/j.annonc.2020.07.010 1323
Annals of Oncology G. Curigliano et al.Which preventive measures do you suggest for health care
workers?
STATEMENT 5: PPE should be provided to all health care
professionals and used meticulously. Health care workers
in enclosed spaces should wear eye protection, a gown
and a surgical mask or, if available, a filtering face piece
(FFP), and practice hand hygiene or protection (gloves).
Swab testing should be offered to all symptomatic health
professionals.
We recommend routinely testing health care workers if
PCR tests are available according to testing intervals defined
by local health authorities taking into consideration the
epidemiological characteristics of SARS-CoV-2 spread. In
every setting, all health care workers should wear surgical
masks, glasses and practice hand hygiene. If health care
workers screen positive for fever or respiratory symptoms,
the consensus advice is firmly for swab testing and to
abstain from work/home quarantine until a swab is
negative.16,17
We suggest implementing serological evaluations of
established validity in health care workers in order to depict
an epidemiological landscape of the pandemic in this
setting.
Is there any different value/indication for the use of
granulocyte colony-stimulating factors during the COVID
pandemic?
STATEMENT 6: To lower the risk of febrile neutropaenia,
consider expanding the indication of granulocyte colony-
stimulating factor (G-CSF) for patients with intermediate
(10%e20%) and high risk for febrile neutropaenia (>20%)
and specifically for elderly patients with comorbidities.
Given the COVID-19 infection risk specifically in patients
with solid tumours not treated with curative intent, one
should consider equally effective treatments unlikely to
induce febrile neutropaenia. There should be clear evidence
to support using ChT regimens with higher neutropaenia
risk. Moreover, to lower the risk of febrile neutropaenia, the
indication for G-CSF can be expanded.18,19 The theoretical
raised concern of acute respiratory failure due to G-CSF-
induced leukocyte recovery in patients with a pulmonary
infection due to COVID-19 does not outweigh the benefit.
Of note, cyclin-dependent kinase 4/6- or poly-adenosine
diphosphate ribose polymerase-inhibitor-induced neu-
tropaenia has not yet demonstrated a clear increase in
associated viral infections.
How to prevent and manage thromboembolic events in
patients with COVID-19
STATEMENT 7: In patients with cancer and COVID-19,
there is an increased risk of thromboembolic events and
associated complications such as lung vessel obstructive
thrombo-inflammatory syndrome. Prophylaxis using low
molecular weight heparin (LMWH) or novel oral antico-
agulants (NOACs) is recommended.
In general, prophylaxis of thromboembolic events should
be continued according to existing guidelines. In unclear1324 https://doi.org/10.1016/j.annonc.2020.07.010cases for prophylaxis according to guidelines, thromboem-
bolic prophylaxis may be initiated rather than withheld.20e22
Patients should receive careful monitoring to prevent
possible bleeding complications. Patients hospitalised with a
confirmed diagnosis of COVID-19 should receive prophylaxis
of thromboembolic events using LMWH or fondaparinux or
even unfractionated heparin if critically ill with a significantly
reduced kidney function. When direct oral anticoagulants
are used, possible drug interactions with medications that
are tested for use against COVID-19 have to be considered.
The role of full anticoagulation in severely ill patients with
COVID-19 remains controversial at this time.
Which tests are standard for detection of SARS-CoV-2?
STATEMENT 8: Detection of SARS-CoV-2 RNA by means of
RT-PCR is the current gold standard for diagnosis of acute
infection with the causative organism of COVID-19.
Tests used in the diagnosis of COVID-19 include assays
based on RT-PCR, isothermal nucleic acid amplification, viral
culture, antigen testing and serology. The current gold
standard and most widely used assays are based on
RT-PCR.23,24 Target genes tested include RNA-dependent
RNA polymerase (RdRp), open reading frame (ORF1), En-
velope (E) and nucleocapsid (N) genes of the SARS-CoV-2
genome. The turnaround time is usually 6 to 8 h but can
be as rapid as 45 min.
False-negative results may be due to improper sampling,
degradation of the viral RNA during shipping/storage, low
viral loads, incorrect nucleic acid extraction, presence of
amplification inhibitors and mutation(s) in the RT-PCR target
region. A false positive is mostly due to sample cross
contamination.25
A detection result proving the presence of viral RNA
sequence in the sampling area, e.g. nasopharynx, is
interpreted as the person having the potential to spread
SARS-CoV-2 to other individuals. However, viability of
SARS-CoV-2 can only be proven by viral culture. Thus, the
interpretation of a positive detection should be carefully
examined. Timing of sampling during the course of the
disease, quantification of the detected sequence
and method of detection may affect the biological
consequence.
The role of computed tomography (CT) screening is
controversial and may play a role in regions with a high
prevalence of COVID-1926 but it should not be used
routinely to screen or diagnose COVID-19.27
Can a blood-derived Ab test (imunoglobulin M and/or
imunoglobulin G) replace testing for SARS-CoV-2
nucleic acid?
STATEMENT 9: Serological Ab tests cannot replace testing
for the SARS-CoV-2 nucleic acid. They can be used for
longitudinal detection of seroconversion and seropreva-
lence in individuals previously positive for SARS-CoV-2.
SARS-CoV-2 Ab tests are intended for use as an aid in
identifying individuals with an adaptive immune
response to SARS-CoV-2, indicating recent or priorVolume 31 - Issue 10 - 2020
G. Curigliano et al. Annals of Oncologyinfection by detecting Abs in human blood. The Abs are
part of the body’s immune response to exposure and not
the virus itself; therefore, such testing is not used for
diagnosis of active infection. RT-PCR currently remains
the reference standard for diagnosing infections, with
high sensitivity and accuracy in the acute phase of
illness.28e31
However, serology tests can play a critical role in broad-
based, public health surveillance, identifying individuals
with prior exposure to SARS-CoV-2 virus and guiding the
response to the pandemic.
A serology test can yield a negative test result during the
early stage of disease, as Abs take several days to be
generated after exposure to the virus. A false positive result
may be due to cross-reactivity (to a coronavirus type other
than the current pandemic novel strain), which heavily
impacts the sensitivity and specificity of the test.
At this time, it is unknown how long Abs persist following
infection and if the presence of Abs confers long-term
protective immunity.Should a patient without clinical infection signs/symptoms
but with a positive SARS-CoV-2 PCR after COVID-19 be
regarded as infected and infectious?
STATEMENT 10: Patients’ infectivity for SARS-CoV-2 is
determined by the presence of the virus in different body
fluids, secretions and excreta. The persistence and clear-
ance of viral RNA from different specimens of patients
with COVID-19 remain unclear. We need longitudinal
studies to distinguish early asymptomatic patients testing
positive from patients recovered from COVID-19 who still
test positive by RT-PCR as their infectivity may differ.
There is an urgent need for information on immunity and
infectivity in specific sites of the body. Investigators have
reported a detailed virological analysis of nine cases of
COVID-19 that provides proof of active virus replication in
tissues of the upper respiratory tract. Pharyngeal virus
shedding was very high during the first week of symptoms,
with a peak at 7.11  108 RNA copies per throat swab on
day 4. Infectious virus was readily isolated from samples
derived from the throat or lung but not from stool samples
despite high concentrations of viral RNA. Blood and urine
samples never yielded virus. Active replication in the throat
was confirmed by the presence of viral replicative RNA in-
termediates in the throat samples. Investigators consis-
tently detected sequence-distinct virus populations in
throat and lung samples from one patient, proving inde-
pendent replication. The shedding of viral RNA from sputum
outlasted the end of symptoms. Seroconversion occurred
after 7 days in 50% of patients (and by day 14 in all
patients) but was not followed by a rapid decline in viral
load. The confirmation of active viral replication in the up-
per respiratory tract has implications for the containment of
COVID-19.32
However, the presence of nucleic acid alone cannot be
used to define viral shedding or infection potential. For
many viral diseases [SARS-CoV, Middle East respiratoryVolume 31 - Issue 10 - 2020syndrome coronavirus (MERS-CoV), influenza virus, Ebola
virus and Zika virus], it is well known that viral RNA can be
detected long after the disappearance of infectious virus.
The immune system can neutralise viruses by lysing their
envelope or aggregating virus particles; these processes
prevent subsequent infection but do not eliminate nucleic
acid, which degrades slowly over time.33Is it safe to treat cancer patients who have tested positive
for SARS-COV-2 with immune checkpoint inhibitors (single
agent or combination)?
STATEMENT 11: For the approved indication of (neo)adju-
vant treatment, where there is a significant survival benefit,
immune checkpoint inhibitors (ICIs) should not be withheld
or delayed in the absence of SARS-CoV-2 infection. In
patients who have tested positive for SARS-CoV-2, the (neo)
adjuvant ICI should be postponed until recovery.
STATEMENT 12: For patients with metastatic melanoma,
intermediate/poor-risk metastatic renal cell carcinoma,
programmed death-ligand 1 (PD-L1)-positive and non-
small-cell lung cancer (NSCLC) and hepatocellular carci-
noma, where there is a clear survival benefit, ICI treat-
ment should be interrupted because of COVID-19.
Restarting ICI treatment should be considered after com-
plete resolution of COVID-19 following negative RT-PCR
testing. A combination of ICI with cytotoxic ChT can be
considered and discussed with patients when the coste
benefit ratio is favourable (overall survival gain) according
to patient risk factors and preference.
In general, there is no convincing evidence that using ICIs
is detrimental to patients, but data are somewhat con-
flicting. If there is a survival benefit for patients in either the
maintenance, adjuvant or neoadjuvant setting, we consider
the riskebenefit ratio is to treat with ICIs. One could argue
about the duration of the treatment and consider stopping
at 1 year. According to real-world data from registries
(CCC19, TERAVOLT, UK), the combination of ChT with ICIs
may be detrimental in SARS-CoV-2-infected patients.Should we avoid giving COVID-19 patients or SARS-CoV-2-
positive individuals high-dose steroids (for symptoms or
grade 3e4 immune-related adverse events management)?
STATEMENT 13: High-dose steroids may represent a po-
tential risk factor for mortality in cancer patients who are
infected with SARS-CoV-2. In case of the need to manage a
grade 3e4 immune-related adverse event (irAE), if
possible, switch to another immunosuppressant agent.Should we avoid giving combinations of anti-cytotoxic
T-lymphocyte-associated protein 4 plus anti-PD-(L)1
checkpoint inhibitors in order to decrease the risk of grade
3e4 irAEs and prefer sequential administration?
STATEMENT 14: The combination of anti-cytotoxic
T-lymphocyte-associated protein 4 (CTLA4) plus anti-PD-
(L)1 should be given if the patient’s disease requires
such ICI treatment (in case of an approved indication), inhttps://doi.org/10.1016/j.annonc.2020.07.010 1325
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and anti-CTLA4 agents is as effective or less toxic.
The risk assessment depends on the local prevalence of
COVID-19. The risk of dying from cancer is higher than the
risk of fatal COVID-19 disease, a fact that should be dis-
cussed with the patient. Reported real-world data from the
CCC19, UK and TERAVOLT registries support the suggestion
that immunotherapy is not associated with a risk of dying
from COVID-19. Nevertheless, the same data from TERA-
VOLT indicate that the combination of ChT with other
therapies, including ICIs, may increase the risk of death in
SARS-CoV-2-infected patients [hazard ratio (HR) for death
1.71; 95% confidence interval 1.12e2.63].34e46What should the work-up be for patients with radiological
evidence of pneumonitis/pulmonary abnormalities/
dyspnoea while receiving ICI treatment during the SARS-
CoV-2 pandemic?
STATEMENT 15: For the differential diagnosis of an irAE
from SARS pneumonitis, a nasopharyngeal swab should be
obtained for PCR and a high-resolution thoracic CT scan
should be carried out. If negative, a broncho-alveolar
lavage (BAL) should be considered (increased risk for
pulmonary oncology team) for differential diagnosis of
irAEs versus COVID-19.
The physician should take into account a range of
epidemiological, clinical, tumour and treatment-related
factors. One the one hand, if the clinical/radiological sus-
picion for pneumonitis due to ICI is high, immediate steroid-
based therapy may be implemented before SARS-CoV-2 PCR
test results are available. On the other hand, if a diagnosis
of COVID-19-related pneumonitis is likely in the presence of
a negative pharyngeal PCR test, repeating the swab and
proceeding to BAL for PCR testing may be necessary. Of
note, the risk of a BAL procedure to the health care worker
is high; accordingly, it should be discussed with the pul-
monology team and be implemented only when positive or
negative results will have an epidemiologic or therapeutic
impact, with appropriate risk-mitigating safety measures.Can tyrosine kinase inhibitors of the phosphoinositide
3-kinase/AKT/mammalian target of rapamycin, RAS/RAF/
MEK axis modulate our immune response and lower its
ability to control COVID-19 infection?
STATEMENT 16: Tyrosine kinase inhibitors (TKIs) of the
phosphoinositide 3-kinase (PI3K)/AKT/mammalian target
of rapamycin (mTOR) or RAS/RAF/MEK axis can interfere
with critical pathways involved in innate or adaptive im-
mune responses. The decision to withhold therapy with
these TKIs depends on the riskebenefit balance. Conse-
quently, the magnitude of benefit (ESMO-Magnitude of
Clinical Benefit Scale) from the TKI should be considered in
a tumour-specific context in the decision-making process
until more clinical data are available.
The PI3K/AKT/mTOR pathway is important for survival,
proliferation and migration of macrophages, which are an1326 https://doi.org/10.1016/j.annonc.2020.07.010essential component of the immune ‘clean-up’ process.
Everolimus is known to be an immunosuppressant for solid
organ transplant patients. There are conflicting preclinical
data on the role of the mitogen-activated protein kinase
(MAPK) pathway, some indicating an important role in
adaptive and innate components of the immune system,
while others involve MAPK in suppression of immune cell
trafficking.37e40 Consequently, although we may speculate
that PI3K/AKT/mTOR or MAPK inhibitors might potentially
compromise immune function and response to SARS-CoV-2
infection, preliminary data from the CCC19 and TERAVOLT
registries did not establish an association of non-cytotoxic
targeted therapies with COVID-19-related mortality (HR
1.04 in both registries).
The decision to withhold therapy with these TKIs de-
pends on the balance between risk and benefit and might
vary from one cancer type to another, so the magnitude of
benefit from the TKI should be considered in a tumour-
specific context in the decision-making process. Specif-
ically, as the indication of PI3K/AKT/mTOR inhibition for
lung cancer is minimal, not recommending these drugs for
lung cancer management during the pandemic is a
reasonable strategy. As for other indications such as breast
cancer, mTOR inhibition is largely limited to later lines of
therapy as, despite the positive study outcomes, the impact
is relatively minor. In contrast, in melanoma, BRAF and MEK
TKI combinations appear relatively safe without the risk of
irAEs or the need to use high-dose steroids.
Should TKIs be suspended during a patient’s active SARS-
CoV-2 infection?
STATEMENT 17: Due to the acute kinetics of COVID-19, it is
reasonable to withhold TKI therapy in patients with
oncologically stable disease until the patient recovers. TKIs
may not be interrupted in patients with less severe COVID-
19 or in those with targetable oncogene-addicted, high-
volume tumours at high risk of flare upon TKI
discontinuation.
Most patients who have previously responded to TKIs
would remain stable for a number of weeks. As COVID-19 is
an acute illness during which most patients may recover or
succumb within days, it is reasonable to withhold the TKI in
oncologically stable patients until the patient recovers. The
severity of the SARS-CoV-2 infectious syndrome should
obviously be taken into consideration. Of note, preliminary
data from the CCC19 and TERAVOLT registries did not
establish an association of non-cytotoxic, targeted therapies
with COVID-19-related mortality (HR 1.04 in both regis-
tries).34,35 Consequently, TKIs should not be interrupted in
patients who need them, such as those in the initial weeks
of therapy and without a fully established antitumour
beneficial response and those with targetable, oncogene-
addicted tumours such as lung cancer in which there is a
risk of a flare effect associated with TKI discontinuation
(high-risk population for flare such as shorter time to
disease progression, pleural effusion and central nervous
system involvement).41Volume 31 - Issue 10 - 2020
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solid tumours during the COVID-19 pandemic?
Breast cancer.
STATEMENT 18: For breast cancer patients in the curative
setting, regimens and doses of adjuvant/neoadjuvant
systemic therapies should be followed, always preceded
by a multidisciplinary discussion, riskebenefit analysis and
discussion with the patient. Significant delays should be
avoided and protective/supportive measures imple-
mented (growth factor support, less immunosuppressive
regimen selection).
For cancers in the curative setting, the riskebenefit
balance clearly favours maintaining systemic treatment
according to guidelines during the COVID-19 pandemic and
therefore standard indications, regimens and doses of
adjuvant/neoadjuvant systemic therapies should always be
followed, preceded by a multidisciplinary discussion and
avoiding as much as possible significant delays. Some
adjuvant/neoadjuvant systemic therapies are associated
with a significant risk of immunosuppression, particularly
ChT, which can increase the risk of severe complications of
SARS-CoV-2 infection. Therefore, relevant supportive mea-
sures should be implemented such as prophylactic use of
hematopoietic growth factors in all regimens with a me-
dium/high risk of immunosuppression, the use of dose-
dense (q2weeks) regimens when appropriate to decrease
the number of visits to the hospital, or conversely, the use
of weekly regimens with low risk of immunosuppression
(despite being associated with a higher number of visits).
Some types of adjuvant/neoadjuvant systemic therapies
are in principle not associated with risk of complications of
COVID-19 and should therefore be used as recommended
by the guidelines, particularly anti-human epidermal
growth factor receptor 2 and endocrine therapies. In situ-
ations where the riskebenefit of adjuvant/neoadjuvant
systemic ChT is controversial or uncertain, it may be wiser
to decide against that treatment during the COVID-19
pandemic, but always after careful discussion with the
patient.42
Lung cancer.
STATEMENT 19: In stage IIeIII NSCLC, adjuvant ChT (with
concurrent or sequential RT in stage III) is recommended
for fit, young patients without significant comorbidities,
after an informed discussion with the patient. In the event
of lack of surgical resources, neoadjuvant ChT followed by
surgery may be considered in highly selected subsets of
patients.
Adjuvant ChT should be considered in the presence of
pathological N1 or N2 disease and should be proposed in
patients who are fit and younger than 70 years of age while
it should be withheld in frail, elderly patients with signifi-
cant comorbidities. Adjuvant ChT could start 6e10 weeks
post-surgical resection. The COVID-19 local epidemic profile
and intensity should be taken into consideration for the
decision-making process since absolute survival benefits
from adjuvant ChT in lung cancer patients is not as sub-
stantial as in breast cancer.Volume 31 - Issue 10 - 2020Neoadjuvant ChT (enabling deferral of surgery by 3
months) should be considered in clinical stage II patients
suitable for a surgical approach with curative intent.Rectal cancer.
STATEMENT 20: Switching to short-course preoperative RT
(SCPRT) (5 3 5 Gy) in rectal cancer rather than standard
long-course chemoradiotherapy (CRT) schedules should be
considered.
A preference for SCPRT (5  5 Gy) is justifiable in rectal
cancer patients during the COVID-19 pandemic rather than
standard long-course CRT schedules. SCPRT (5  5 Gy) is
flexible in timing and provides a reduced in-hospital footfall
during the COVID-19 pandemic, allowing better adherence
to social distancing recommendations while avoiding the
need for concomitant ChT. For easily resectable cancers,
when SCPRT with immediate surgery and long-course con-
current CRT have been directly compared in randomised
phase III trials, no differences in oncological outcomes (local
control, rate of metastases, disease-free survival) or late
effects and quality of life (QoL) were demonstrated.43,44
Recent clinical data may support administration of short-
course RT followed by systemic ChT and deferral of surgery
by a few weeks in the event of lack of surgical resources.In lung cancer patients with no COVID-19 symptoms
treated with curative-intent RT, should we reduce RT
fractionation to minimise the number of hospital visits?
STATEMENT 21: Patients undergoing adjuvant or definitive
lung RT are at risk of severe complications from COVID-19.
In order to reduce the risks of treatment and hospital
attendances during the COVID-19 pandemic, the use of
reduced-fractionation RT should be discussed by the
multidisciplinary tumour board as well as with the patient
in order to balance the riskebenefit of the approach.
The global COVID-19 pandemic presents a challenge to
the delivery of radical RT to patients with lung cancer. Pa-
tients undergoing lung RT are in the group at highest risk of
severe complications and death from COVID-19 due to their
age, comorbidities and side-effects of their anticancer
treatments. Therefore, there is a need to reduce the risks of
treatment and hospital attendances during the COVID-19
pandemic.
Limited clinical data indicate that it is feasible to identify
reduced-fractionation and curative-intent RT regimes in
lung cancer, while taking into careful consideration param-
eters such as organs-at-risk dose constraints, limitations and
practicalities related to implementation. Requirements to
implement such change in practice will depend on the local
incidence of COVID-19 and staffing resources. Imple-
mentation should be discussed with other specialist lung
MDT members and importantly with patients. The risks and
benefits of treatment and uncertainties about toxicity from
reduced fractionation where there is limited experience in a
department should be an essential component of the
consent process.45,46https://doi.org/10.1016/j.annonc.2020.07.010 1327
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thoracic RT in a lung cancer patient with documented
COVID-19?
STATEMENT 22: In the case of a diagnosed COVID-19 pa-
tient with lung cancer, we recommend continuing
curative-intent thoracic RT, taking into consideration the
severity of the COVID-19 clinical syndrome, the risk of
tumour recurrence/progression with treatment interrup-
tion and the local resources.
Mature data on the impact of continuation of RT in
patients with COVID-19 are lacking, though preliminary
data from the CCC19 and the TERAVOLT registries did not
establish an association between RT and COVID-19 mor-
tality. Still, it is acknowledged that patients with cancer
face a higher risk of morbidity and mortality related to
COVID-19 for a multitude of reasons. Currently, we are
unable to conclude if the different treatment modalities
harbour equal risks, given the small cumulative number of
patients who received RT in these studies and the short
follow-up. Moreover, long-term data are awaited to
appreciate the effect of treatment interruption on cancer
control and survival in these patients. From retrospective
series dating from the 1980s and 1990s, we know that
breaks during RT are associated with a higher rate of
locoregional recurrences in patients with head and neck
cancer and NSCLC.47 For COVID-19-positive patients,
discussing the risks of worsening illness with continuing RT
versus the risk of tumour recurrence/progression with
treatment interruption is recommended. If a patient with
mild COVID-19 consents to continuing with treatment and
delivery of treatment is possible, we recommend consid-
ering a change in the fractionation schedule to a hypo-
fractionated regimen to reach a tumour equivalent of
60 Gy. Available local resources are a key determinant of
therapeutic strategies to be selected. Given the infectivity
of the SARS-CoV-2 virus, regardless of the extent of
infection control measures, COVID-19-positive patients
will pose a health risk when in close proximity to other
individuals. Ideally, these patients should be treated in
dedicated COVID-19 RT treatment facilities, where they
can be isolated to limit virus transmission. An alternative
would be to schedule the treatment of such patients at the
end of the working day followed by meticulous disinfec-
tion and sanitisation of the facility.48,49Are cancer patients at highest risk of severe forms of
COVID-19?
STATEMENT 23: Active and progressing status of cancer,
advanced age, poor performance status (PS), smoking
status, comorbidities and possibly type of cancer (hae-
matological, thoracic malignancies) and administration of
cytotoxic ChT have been initially identified as significant
risk factors for severity and mortality of COVID-19.
There is plausible concern that diagnostic pathways and
cancer treatment modalities may expose cancer patients to
a greater risk of acquiring SARS-CoV-2 infection than would
be the case if they were able to maintain effective social1328 https://doi.org/10.1016/j.annonc.2020.07.010distancing at home. The limited experience reported to-date
indicates that the risk of SARS-CoV-2 infection might be
comparable with the global population (11% of cancer pa-
tients tested positive at Gustave Roussy in France).50 This
encouraging observation may reflect enhanced precautions,
adoption of protective measures (such as social distancing,
handwashing, masks) and reconfiguration of cancer care
services to maximise patient safety.
It is unclear whether there is an increased risk of death
associated with specific oncological scenarios. Early pub-
lished case series from China suggested that cancer is com-
parable to poorly-controlled hypertension and diabetes as a
risk factor for death from COVID-19. These data are not suf-
ficiently detailed with regard to the granularity of medical
conditions in order to derive generalisable and actionable
conclusions. The over-representation of older people with
comorbidities and other risk factors in the cancer population
are highly likely to be confounders in this association.
Preliminary data derived from cohort studies (CCC19,
TERAVOLT, UK) are now available but should be interpreted
with caution.34,35 Selection bias with major recruitment of
patients presenting with cancer and symptomatic COVID-19
in hospital settings and under-representation of mild or
asymptomatic patients in the community enriches the cohort
for patients more likely to experience poor outcomes. These
differences in cohort selection may explain the differences in
the preliminary data suggesting 29% of 897 UK cancer pa-
tients with a diagnosis of COVID-19 died50 compared with
14.6% in France.51 Overall, data from these registries
commonly identify advanced age, male sex, poor PS, pres-
ence of comorbidities and active/progressing malignancy as
risk factors for increased COVID-19 mortality or severity.
Immunotherapy or targeted therapies were not identified as
risk factors whereas discordant results were observed for
cytotoxic ChT: it was not correlated with mortality in the UK
and CCC19 registries but was in the TERAVOLT study.
COVID-19-related mortality has been reported to be
higher in cases of haematological malignancies and lung
cancer.52 In the TERAVOLT study, there was a 25% mortality
rate among SARS-CoV-2-infected patients with an underly-
ing diagnosis of lung cancer.34 Perioperative infection with
COVID-19 is associated with a higher risk of mortality, so
preoperative screening with RT-PCR and chest imaging is
routinely carried out.53,54Which patients with cancer should or should not access
ICUs?
STATEMENT 24: A decision on ICU transfer depends on the
ICU resource strain and is to be adapted according to the
R0 index and ECDC pandemic scenario; the ethical value of
maximising the number of patients who survive COVID-19
with a reasonable life expectancy has the highest priority.
Neither stage nor specific diagnosis has been validated as
a predictor of survival of a severe acute concurrent illness
such as COVID-19. Staging alone should not be used for
triage as patients with stage IV cancer are extremely het-
erogeneous in terms of prognosis and their degree ofVolume 31 - Issue 10 - 2020
G. Curigliano et al. Annals of Oncologyphysiological compromise or reserves. Some patients with
advanced cancers have expressed advanced directives
ruling out ventilation support. However, it would be unlikely
that a subgroup of patients suffering from physiological
compromise from their cancer would survive this kind of
acute concurrent infection even with ventilation support.
The decision relies on the availability of ICU resources and is
to be adapted according to the evolution of the pandemic.
The ethical value of maximising the number of patients who
survive COVID-19 with a reasonable life expectancy has the
highest priority during the pandemic. Patients with hae-
matological malignancies and primary or metastatic
tumours in the lung are at greater risk of ICU referral,
development of severe critical illness and use of invasive
ventilation. The oncology team has to discuss with patients
and their caregivers the possibility of referral to the ICU,
taking into consideration concomitant risk factors for
adverse outcomes including: disease, stage, intent of the
antitumour treatment and reasonable life expectancy. A
shared decision has to be reached and documented. A
triage system involving the oncology team must be set up to
ensure a fair assessment of cancer patients in the event of
admission to the ICU and in case of worsening of patients’
clinical conditions while in the ICU.55,56During the COVID-19 pandemic, has the riskebenefit
profile for including an individual patient in a clinical trial
changed?
STATEMENT 25: The riskebenefit profile for including an
individual patient in a clinical trial should be adapted to
the R0 index and case load of the pandemic as well as
health care organisation characteristics and resources.
Clinical trial sponsors are accountable for conducting an
updated risk assessment for all clinical trials, adjusting the
conduct of clinical trials accordingly, and informing in-
vestigators and clinical trial participants of the updated risk
assessment and any changes to be implemented. In-
vestigators play an important role in the accuracy of the
riskebenefit assessment by promptly informing the sponsor
of new risks identified and by making individual decisions
about the potential risks benefits to an individual patient
based on their medical history and situation. It is imperative
that the assessment of potential changes in riskebenefit
take into account the specificities of each clinical trial
population, the intervention under investigation and the
local situation at each clinical trial site. The riskebenefit
assessment may or may not change materially for each
clinical situation and, depending on the aforementioned,
not taking part in a cancer clinical trial may pose a bigger
risk to some patients than entering the trial under pre-
cautions against the risk of COVID-19. Investigators should
also keep in mind that cancer patients may be eligible for
clinical trials for the prevention or treatment of COVID-19
or its complications and stay informed of such clinical trial
opportunities. COVID-19 patients with cancer have sub-
stantially higher risk of severe outcomes compared with
patients without cancer, particularly in those withVolume 31 - Issue 10 - 2020metastatic cancer. Patients should be thoroughly informed
about potential changes arising from the outbreak by using
web technology for communication with the investigator
team, possible social isolation during COVID-19 outbreak
and closer collaboration with general practitioners or local
laboratories.57,58
How do we decide whether to deviate from a clinical trial
protocol (for riskebenefit reasons) and how do we handle
the deviations that take place?
STATEMENT 26: During the COVID-19 pandemic, de-
viations from a clinical trial protocol (for riskebenefit
reasons) may be considered provided there is rigorous
documentation in the medical record of the patient and
that this is communicated as soon as possible to the
sponsor. There are no acceptable deviations in safety
reporting.
During the COVID-19 pandemic, deviations from clinical
trial protocols seem unavoidable if only for logistical rea-
sons. Treating physicians should remain as close as possible
within the provisions of clinical trial protocols so that the
riskebenefit balance of the clinical trial remains acceptable.
Frequent and open communication between clinical trial
sites and clinical trial sponsors is paramount. Documenta-
tion of any deviation and communication of deviations to
the clinical trial sponsor are necessary so that sponsors can
monitor changes in the riskebenefit balance of the clinical
trial, declare such deviations to the appropriate authorities
and plan amendments to the clinical trial protocols. Exam-
ples of such deviations include but are not limited to
remote methods of patient monitoring, investigational drug
delivery and change of laboratories for diagnostic tests due
to travel restrictions and the need for social distancing.
Regardless, adaptations to the pandemic should not change
the processes and timelines of safety reporting and phar-
macovigilance declaration, which should be done
completely and promptly even when using remote methods
of patient assessment.56,57
Patient-reported outcomes merit special attention as
clinical trial end points. Although remote patient moni-
toring may not change the self-reporting ability of
patients, measures such as QoL and physical functioning
are likely to be impacted by the social distancing and other
measures in response to the pandemic. Investigators and
clinical trial sponsors should assess whether to continue
collecting such measures and how to handle the effect of
the pandemic in the analysis of the clinical trial data.
Do we continue to advocate and emphasise the need for
cancer clinical trials for our patients to other stakeholders
including but not limited to hospital systems, insurers and
sponsors?
STATEMENT 27: During the COVID-19 pandemic, we
should continue lobbying for promoting clinical cancer
research to find better therapeutic options for patients
with neoplasms. Cancer is and will continue to be one of
the most significant causes of morbidity and mortality.https://doi.org/10.1016/j.annonc.2020.07.010 1329
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lives of cancer patients both for individuals participating in
trials and through development of new drugs. Failure to
invest in ongoing and future clinical trials may lead to
‘collateral damage’ from COVID-19 for individuals currently
and collectively for cancer patients in the future. Within the
hospital system, it is right and fully accepted that resources
will be directed toward COVID-19-related activity and
restructuring. However, cancer patients still require treat-
ment even during the current pandemic. Cancer treatment
is not elective or optional. The benefits of cancer clinical
trial participation are broader than the benefits for an
individual since they also raise clinical standards. It is well
documented that even patients who are not active partic-
ipants in clinical trials have better outcomes in a research-
active environment. Furthermore, decreased cancer clin-
ical trial activity and deskilling of clinical trial staff repre-
sents a loss of valuable experience in addition to financial
investment.58,59
For academic and commercial sponsors, we must retain a
long-term vision and a sense of proportionality. Cancer was
one of the most significant causes of mortality pre-COVID-
19 (9.6 million deaths globally in 2018) and whatever the
shape of the post-COVID-19 era, this will not change. We
can work with sponsors to harness the energy that has led
to rapid and radical changes being enacted in health care
systems. We should facilitate similar changes in clinical trial
design and delivery to allow faster and more economical
drug development. In order to maintain and strengthen
sponsor relationships, we should demonstrate our
commitment and capacity for delivering trials safely for
patients and with ongoing high standards for data and
biospecimen collection within clinical protocols, which have
been adapted to an intra- and post-COVID-19 environment.If clinical trial activities are restricted or resources are
limited, how do we select the most relevant clinical trials
for continuation or initiation?
STATEMENT 28: While we globally continue promoting
clinical cancer research as the only way to find better
therapeutic options and to improve cancer prognosis, we
should continue ranking priorities in terms of value for the
most appropriate clinical research.
Depending on the level of resource available for clinical
trial activity, interventional studies with the following
characteristics could be prioritised: (i) trials with a high
likelihood of benefit (e.g. promising activity in early phase
or molecularly-selected therapy), (ii) trials where the risk is
lower in the experimental arm than standard of care
(e.g. targeted or immunotherapy versus cytotoxic ChT), (iii)
trials where treatment is of lower intensity than standard of
care (e.g. monthly versus biweekly visits or oral rather than
i.v. medication) and (iv) trials where there is no standard of
care available in that setting. Finally, trials with a high risk of
use of intensive care facilities in areas with high COVID-19
activity may temporarily be considered of lower priority.1330 https://doi.org/10.1016/j.annonc.2020.07.010CONCLUSIONS
Using a structured method and relying on a diverse panel of
experts, we have developed a detailed set of clinical
statements to guide health care professionals and assist
them in overcoming many of the clinical and technical ob-
stacles related to diagnosis, risk assessment, response
assessment, surgical planning, RT and medical treatment
during the COVID-19 pandemic. Ultimately, this set of
statements will serve as a dynamic knowledge repository
that will be better informed by accumulating data on SARS-
CoV-2 biology, COVID-19 pandemic characteristics, the risks
of COVID-19 and its modulating factors in cancer patients
and, finally, on optimal cancer care in the presence of the
virus.
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